Eli Lilly and Company (NYSE:LLY) is one of the most frequently discussed stocks on Cramer’s morning show. He is a fan of the firm not only due to its lead in the weight loss market but also due ...

Eli Lilly and Company (LLY)’s share was trading at $765.68 as of 5th June. LLY’s trailing and forward P/E were 62.30 and 35.09 respectively according to Yahoo Finance.

US Big Pharma firm Eli Lilly & Co. agreed to buy gene-editing biotech company Verve Therapeutics Inc. for $1.3 billion as the drugmaker focuses its investments in experimental medicine for a ...

June 17 (UPI) -- Eli Lilly and Company said Tuesday it will buy out Boston-based Verve Therapeutics Inc. in a billion dollar deal with plans to advance Verve's new line of experimental cardiac ...

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals in the United States, Europe, China, Japan, and internationally. The company offers Basaglar, Humalog, Humalog Mix 75/ ...

Lilly is expected to post earnings of $5.56 per share for the current quarter, representing a year-over-year change of +41.8%. Over the last 30 days, the Zacks Consensus Estimate has changed +0.5%.

The pill could further broaden access for patients in the U.S. and internationally.” Eli Lilly and Company (NYSE:LLY) is in 21st position on our list of 30 Most Popular Stocks Among Hedge Funds.

When Eli Lilly & Co. on Tuesday announced pricing and packaging changes for its popular weight-loss drug Zepbound, the drugmaker said it was expanding access for people living with obesity — but ...

Indianapolis-based Eli Lilly and Co. became the first company to commercialize insulin in 1923, two years after University of Toronto scientists discovered it.

Chugai Pharmaceutical Co. Ltd. CHGCY believes its anti-muscle-wasting drug could be used alongside Eli Lilly And Co.’s LLY oral obesity pill, orforglipron. Roche Holdings AG RHHBY is a major ...

Eli Lilly & Company (NYSE:LLY) is one of billionaire Stan Druckenmiller’s top stock picks with huge upside potential. Bernstein SocGen Group reaffirmed its Outperform rating and $1,100 price target ...